DENVER, Nov. 29, 2021 /PRNewswire/ -- Dialysis
patients who received mRNA COVID-19 vaccines had a lower risk of
COVID-19 diagnosis post-vaccination and were less likely to be
hospitalized or die following breakthrough infection than
unvaccinated patients, according to a DaVita Clinical Research
(DCR) study published online ahead of print by the Journal
of the American Society of Nephrology.
"This is the first large study aimed at understanding the
clinical effectiveness of COVID-19 vaccines in this highly
vulnerable patient population," said Dr. Steven Brunelli, MCSE, vice president for DCR.
"Our observations provide reassurance that COVID-19 mRNA
vaccination is an effective clinical strategy to help protect these
patients from COVID-19 and from associated hospitalization and
death."
More than 500,000 Americans diagnosed with end stage kidney
disease (ESKD) receive life-sustaining dialysis care. Despite being
at high risk for COVID-19 due to underlying health conditions that
compromise their immune systems, these patients were not
represented in the Phase III clinical trials of BNT162b
(Pfizer/BioNTech) and mRNA-1273 (Moderna) SARS-CoV-2 vaccines.
To assess COVID-19 vaccine effectiveness in this patient
population, researchers evaluated electronic health records of
35,206 DaVita dialysis patients vaccinated with Pfizer/BioNTech or
Moderna vaccines between Jan. 1 and Feb. 25,
2021. These patients were matched to unvaccinated controlled
groups and followed over time to observe future COVID-19 infections
and related clinical outcomes.
Researchers observed that the Pfizer/BioNTech and Moderna
vaccines were 78% and 73% effective in preventing COVID-19
infections, respectively. The study indicated that vaccinated
dialysis patients who experienced a breakthrough COVID-19 infection
were also less likely to be hospitalized or die from COVID-19 as
compared to unvaccinated patients diagnosed with COVID-19. In
addition, among vaccinated dialysis patients, SARS-CoV-2 antibodies
were detected in rates similar to those seen in the broader Phase
III clinical trials.
Since the onset of the COVID-19 pandemic, DCR has conducted
several studies to better understand how the novel coronavirus
behaves in medically vulnerable patients with ESKD. Related
research efforts also include two prospective studies in ESKD
patients: one investigating the influence of prior infection/
naturally acquired antibodies on the future risk of infection, and
a second one (ongoing) studying the genetic basis for
susceptibility to more severe cases of COVID-19.
To learn more about DaVita Clinical Research,
visit DaVitaClinicalResearch.com.
About DaVita Clinical Research
DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita
Inc., is the research arm of DaVita. DCR innovates through
retrospective research aimed at improving clinical outcomes. DCR
assists pharmaceutical and medical device companies in the design,
recruitment and completion of clinical trials using its renal
research site network. To learn more about DCR,
visit DaVitaClinicalResearch.com.
About DaVita Inc.
DaVita (NYSE: DVA) is a health care provider focused on
transforming care delivery to improve quality of life for patients
globally. The company is one of the largest providers of kidney
care services in the U.S. and has been a leader in clinical quality
and innovation for more than 20 years. DaVita cares for patients at
every stage and setting along their kidney health journey—from
slowing the progression of kidney disease to helping to support
transplantation, from acute hospital care to dialysis at home. As
of September 30, 2021, DaVita served 203,000 patients at 2,822
outpatient dialysis centers in the United States. The
company also operated 333 outpatient dialysis centers in ten
countries worldwide. DaVita has reduced hospitalizations, improved
mortality, and worked collaboratively to propel the kidney care
industry to adopt an equitable and high-quality standard of care
for all patients, everywhere. To learn more,
visit DaVita.com/About.
Contact Information
Media:
Halie Peddle
(303) 550-6349
Halie.Peddle@DaVita.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/davita-clinical-research-study-indicates-effectiveness-of-mrna-covid-19-vaccines-in-dialysis-patients-301432614.html
SOURCE DaVita Clinical Research